Edgewise Therapeutics, Inc.
A clinical-stage biopharmaceutical company in Boulder, Colorado that makes swallowed pills designed to treat serious muscle diseases. Its drugs tune myosin, the protein that drives muscle contraction, to protect fragile fibers in muscular dystrophies and to ease the stiff, thickened heart muscle of hypertrophic cardiomyopathy. Founded in 2017 by four scientists and drug developers, the company went public on Nasdaq in 2021.
Granted 100.0K · Sold 100.0K
Granted 115.5K · Sold 115.5K
Granted 100.0K · Sold 121.6K
Granted 1.5K · Bought 10.7K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Russell Alan JChief Scientific Officer, Director · 2 transactions | 0% | 123.4K | 100.0K | — | 100.0K |
| Edris BadreddinDirector · 10 transactions | +388.2% | 96.8K | 115.5K | — | 115.5K |
| Donovan Joanne M.CMO · 9 transactions | +92.6% | 54.4K | 100.0K | — | 121.6K |
| Fox Jonathan CDirector · 4 transactions | +99.7% | 24.5K | 1.5K | 10.7K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last year: -326.4K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.